AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16393753 — intervention group
Group type: COMPARATOR
Intervention: Left neutral faces
Number of subjects: 5
Study 14598195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the front of the waist
Number of subjects: 66
Study 14598195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the side of the waist
Number of subjects: 66
Study 14598195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic pedometer placed at the back of the waist
Number of subjects: 66
Study 14598195 — intervention group
Group type: COMPARATOR
Intervention: Hand-tally counter (reference)
Number of subjects: 66
Study 10792114 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 microg daily
Number of subjects: 32
Study 10792114 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8852095 — intervention group
Group type: EXPERIMENTAL
Intervention: Information programme consisting of a group meeting and a brochure
Number of subjects: 128
Study 8852095 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 128
Study 1734572 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine sulfate (EPI)
Number of subjects: 68
Study 1734572 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine sulfate (IM)
Number of subjects: 68
Study 1734572 — intervention group
Group type: COMPARATOR
Intervention: Patient controlled morphine sulfate (PCA)
Number of subjects: 68
Study 6734037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (30 mg)
Number of subjects: 129
Study 6734037 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 129
Study 6734037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nalbuphine (30 mg) and acetaminophen (650 mg)
Number of subjects: 129
Study 6734037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 30787075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco, Exercise and dieT MEssages programme (4 text messages per week for 6 months)
Number of subjects: 683
Study 30787075 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco, Exercise and dieT MEssages programme
Number of subjects: 683
Study 30787075 — intervention group
Group type: COMPARATOR
Intervention: Control group (no text messaging intervention)
Number of subjects: 683
Study 29463159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrofilm polyurethane film dressings
Number of subjects: 62
Study 29463159 — intervention group
Group type: COMPARATOR
Intervention: 5% urea lotion
Number of subjects: 62
Study 27002667 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit resistance training (CRT) program, 5 sessions per week for 6 weeks, in addition to conventional rehabilitation
Number of subjects: 26
Study 27002667 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 26
Study 24677110 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05% four times daily
Number of subjects: 110
Study 24677110 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1% eight times daily
Number of subjects: 110
Study 24677110 — intervention group
Group type: EXPERIMENTAL
Intervention: Difluprednate 0.05%
Number of subjects: 110
Study 24677110 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 110
Study 22560713 — intervention group
Group type: EXPERIMENTAL
Intervention: 50.4 Gy radiotherapy
Number of subjects: 57
Study 22560713 — intervention group
Group type: COMPARATOR
Intervention: Up-front temozolomide
Number of subjects: 57
Study 22560713 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital ICR
Number of subjects: 57
Study 22560713 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital RT plan submission and review
Number of subjects: 57
Study 22560713 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 57
Study 20978259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 579
Study 18482101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 2566
Study 18482101 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 2566
Study 18482101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolcapone (switch from entacapone)
Number of subjects: 2566
Study 18482101 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (switch from tolcapone)
Number of subjects: 2566
Study 18482101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2566
Study 16050943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (0.1-1 mg daily or 0.1-0.8 mg four times a day for 5 or 6 days)
Number of subjects: 3
Study 16050943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (30, 100 or 300 microg three times daily for 14 days)
Number of subjects: 3
Study 16050943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (various doses as mentioned)
Number of subjects: 3
Study 14763223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) (Arlevert [ARL])
Number of subjects: 82
Study 14763223 — intervention group
Group type: COMPARATOR
Intervention: Betahistine dimesylate (12 mg)
Number of subjects: 82
Study 14763223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of cinnarizine and dimenhydrinate (ARL)
Number of subjects: 82
Study 10360138 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 18
Study 10360138 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 18
Study 8952010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 2 g/day
Number of subjects: 97
Study 8952010 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin 3 g/day
Number of subjects: 97
Study 8952010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 2021123 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (20-25% of calories as fat)
Number of subjects: 13
Study 2021123 — intervention group
Group type: COMPARATOR
Intervention: Control diet (35-40% fat)
Number of subjects: 13
Study 7056952 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) at 1600 mg/day
Number of subjects: 0
Study 7056952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butylester (FCB) used well in excess of its presumed therapeutic dose range
Number of subjects: 0
Study 31829910 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP with a 940-nm diode laser
Number of subjects: 126
Study 28869198 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body irradiation to all macroscopic metastatic sites and the primary disease
Number of subjects: 0
Study 28869198 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26096714 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Coaching for Better Mood and Weight (I‐CARE) program
Number of subjects: 404
Study 26096714 — intervention group
Group type: COMPARATOR
Intervention: Usual care enhanced with the provision of a pedometer and information about the health system's services for mood or weight management
Number of subjects: 404
Study 24461067 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based training in the LapSimGyn(®) virtual reality simulator
Number of subjects: 28
Study 24461067 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional structured mentorship during subsequent laparoscopies
Number of subjects: 28
Study 24461067 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 28
Study 20827794 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 409
Study 20827794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 19191674 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/H25 fixed-dose combination (FDC)
Number of subjects: 639
Study 19191674 — intervention group
Group type: EXPERIMENTAL
Intervention: T80/H25 fixed-dose combination (FDC) with additional antihypertensive medication
Number of subjects: 639
Study 17121197 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture Insensitive Primer (MIP) on enamel etched and dry
Number of subjects: 124
Study 17121197 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisture Insensitive Primer (MIP) on saliva-wet enamel
Number of subjects: 124
Study 17121197 — intervention group
Group type: EXPERIMENTAL
Intervention: One Step Self Etching Primer (SEP) on dry field
Number of subjects: 124
Study 17121197 — intervention group
Group type: EXPERIMENTAL
Intervention: One Step Self Etching Primer (SEP) on saliva-wet enamel
Number of subjects: 124
Study 14701777 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA/IDA
Number of subjects: 93
Study 14701777 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA/DNR
Number of subjects: 93
Study 14701777 — intervention group
Group type: COMPARATOR
Intervention: DNR/DNR
Number of subjects: 93
Study 14701777 — intervention group
Group type: EXPERIMENTAL
Intervention: CCG‐2941
Number of subjects: 93
Study 11744584 — intervention group
Group type: COMPARATOR
Intervention: mivacurium
Number of subjects: 60
Study 11744584 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium
Number of subjects: 60
Study 9296409 — intervention group
Group type: COMPARATOR
Intervention: 3 ml 0.17% bupivacaine in 2.66% dextrose without fentanyl (Group I)
Number of subjects: 50
Study 9296409 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml 0.17% bupivacaine in 2.66% dextrose with 10 microg fentanyl (Group II)
Number of subjects: 50
Study 8488993 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure (small metal bullets fastened at point P 6 on each forearm for 24 h)
Number of subjects: 60
Study 8488993 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no specific intervention mentioned)
Number of subjects: 60
Study 3511689 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 60
Study 3511689 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 60
Study 29752026 — intervention group
Group type: EXPERIMENTAL
Intervention: RotaSIIL
Number of subjects: 4092
Study 29752026 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4092
Study 27642130 — intervention group
Group type: EXPERIMENTAL
Intervention: GEN-003 vaccine
Number of subjects: 0
Study 27642130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigens without adjuvant
Number of subjects: 0
Study 27642130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 25133840 — intervention group
Group type: EXPERIMENTAL
Intervention: PA-promoting message
Number of subjects: 101
Study 25133840 — intervention group
Group type: COMPARATOR
Intervention: Healthy eating message
Number of subjects: 101
Study 23392542 — intervention group
Group type: EXPERIMENTAL
Intervention: B6 (250 mg/day) for five months
Number of subjects: 57
Study 23392542 — intervention group
Group type: EXPERIMENTAL
Intervention: B1+B6 (250 mg/day each) for five months
Number of subjects: 57
Study 23392542 — intervention group
Group type: COMPARATOR
Intervention: Diabetic group with nephropathy
Number of subjects: 57
Study 23392542 — intervention group
Group type: COMPARATOR
Intervention: Diabetic group without nephropathy
Number of subjects: 57
Study 21334555 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl pectin nasal spray (FPNS)
Number of subjects: 110
Study 21334555 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release morphine sulfate (IRMS)
Number of subjects: 110
Study 18493261 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (video adventures and rewards for eating fruit and vegetables)
Number of subjects: 435
Study 18493261 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (parental provision and children's consumption of lunchbox fruit, vegetables, and juice)
Number of subjects: 435
Study 18493261 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no intervention)
Number of subjects: 435
Study 17459783 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG‐PET based diagnostic arm
Number of subjects: 0
Study 17459783 — intervention group
Group type: COMPARATOR
Intervention: Conventional diagnostic arm (direct laryngoscopy for all patients)
Number of subjects: 0
Study 17459783 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 0
Study 15327042 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicinal extract (CBME)
Number of subjects: 160
Study 15327042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.75 MAC
Number of subjects: 40
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.0 MAC
Number of subjects: 40
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.25 MAC
Number of subjects: 40
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 0.75 MAC
Number of subjects: 40
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.0 MAC
Number of subjects: 40
Study 11350461 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 1.25 MAC
Number of subjects: 40
Study 9164897 — intervention group
Group type: EXPERIMENTAL
Intervention: sustained-release verapamil
Number of subjects: 13
Study 7695185 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy to prevent restenosis
Number of subjects: 0
Study 7695185 — intervention group
Group type: EXPERIMENTAL
Intervention: Local delivery of drug at the site of injury
Number of subjects: 0
Study 7695185 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of highly specific drugs including local gene therapy
Number of subjects: 0
Study 2687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 50 mg
Number of subjects: 8
Study 2687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 100 mg
Number of subjects: 8
Study 2687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 75 mg
Number of subjects: 8
Study 2687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol 200 mg
Number of subjects: 8
Study 2687007 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 8
Study 2687007 — intervention group
Group type: COMPARATOR
Intervention: Control group not mentioned
Number of subjects: 8
Study 334608 — intervention group
Group type: EXPERIMENTAL
Intervention: Butacote (enteric-coated phenylbutazone) 300 mg daily
Number of subjects: 193
Study 334608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 1200 mg daily
Number of subjects: 193
Study 334608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study 31576471 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational group intervention
Number of subjects: 50
Study 31576471 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 31030296 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC; 20 mg/kg)
Number of subjects: 11
Study 31030296 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 11
Study 29282015 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (single dose)
Number of subjects: 843
Study 29282015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 843
Study 25612795 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led psychosocial intervention (NUCAI)
Number of subjects: 205
Study 25612795 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 205
Study 25715322 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent binge eating symptoms
Number of subjects: 77
Study 25715322 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent depressive symptoms
Number of subjects: 77
Study 23517509 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant with dual acid-etched surface and CaP nanoparticles
Number of subjects: 15
Study 23517509 — intervention group
Group type: COMPARATOR
Intervention: Control implant with dual acid-etched surface
Number of subjects: 15
Study 20030701 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (walking for 30 min at least three times per week) during 4 weeks of external beam radiotherapy
Number of subjects: 65
Study 20030701 — intervention group
Group type: COMPARATOR
Intervention: Standard advice (control group)
Number of subjects: 65
Study 18786565 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG measures of muscle activity in the supposed quiescent limb
Number of subjects: 0
Study 18786565 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement of the involved limb
Number of subjects: 0
Study 17079556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing with 4.0% chlorhexidine
Number of subjects: 15123
Study 17079556 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing with soap and water
Number of subjects: 15123
Study 17079556 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry cord care
Number of subjects: 15123
Study 12814055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency cranial electrostimulation (CES) for 30 minutes a day for 6 weeks
Number of subjects: 16
Study 12814055 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation for 30 minutes a day for 6 weeks
Number of subjects: 16
Study 12814055 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency CES and Sham stimulation
Number of subjects: 16
Study 10870784 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue exercise (5 or more times weekly)
Number of subjects: 117
Study 10870784 — intervention group
Group type: COMPARATOR
Intervention: Reduce exercise (to 3 or fewer sessions of exercise weekly)
Number of subjects: 117
Study 9234649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 5.4 mg t.i.d.
Number of subjects: 32
Study 9234649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 10.8 mg t.i.d.
Number of subjects: 32
Study 9234649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 16.2 mg t.i.d.
Number of subjects: 32
Study 9234649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 21.6 mg b.i.d.
Number of subjects: 32
Study 9234649 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (all doses)
Number of subjects: 32
Study 8129993 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic mebendazole therapy
Number of subjects: 26
Study 8129993 — intervention group
Group type: COMPARATOR
Intervention: Continuous mebendazole therapy
Number of subjects: 26
Study 2885298 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of propranolol
Number of subjects: 6
Study 2885298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31925811 — intervention group
Group type: EXPERIMENTAL
Intervention: EPP EMD + BS
Number of subjects: 30
Study 31925811 — intervention group
Group type: COMPARATOR
Intervention: EPP alone
Number of subjects: 30
Study 29310681 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct anterior approach
Number of subjects: 243
Study 29310681 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral approach
Number of subjects: 243
Study 29310681 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 243
Study 28899891 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anaesthesia (target BIS value 35)
Number of subjects: 0
Study 28899891 — intervention group
Group type: COMPARATOR
Intervention: Light anaesthesia (target BIS value 50)
Number of subjects: 0
Study 25156886 — intervention group
Group type: COMPARATOR
Intervention: APO (doxorubicin, prednisone, vincristine, methotrexate, 6‐mercaptopurine)
Number of subjects: 125
Study 25156886 — intervention group
Group type: EXPERIMENTAL
Intervention: APV (weekly vinblastine)
Number of subjects: 125
Study 23364472 — intervention group
Group type: EXPERIMENTAL
Intervention: 17DD yellow fever vaccine (17DD‐YFV) at doses from 27,476 IU to 31 IU
Number of subjects: 900
Study 20521875 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 13
Study 20521875 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study 18825157 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) meal
Number of subjects: 22
Study 18825157 — intervention group
Group type: COMPARATOR
Intervention: Low Glycemic Index (LGI) meal
Number of subjects: 22
Study 16892929 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight‐week strength training programme in circuit format executed during school hours, one to three times per week for 40‐60 min per session.
Number of subjects: 31
Study 16892929 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 subjects)
Number of subjects: 31
Study 12678140 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitter melon ingestion (patient treatment group)
Number of subjects: 60
Study 12678140 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy without bitter melon (patient control group)
Number of subjects: 60
Study 10781759 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 375 mg/day to 3,000 mg/day
Number of subjects: 131
Study 10781759 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release niacin 1,000 mg/day to 3,000 mg/day
Number of subjects: 131
Study 10781759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 8641928 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF administered as required (single injections, n = 21)
Number of subjects: 41
Study 8641928 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF administered for at least 3 consecutive days (n = 20)
Number of subjects: 41
Study 8641928 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF (both groups)
Number of subjects: 41
Study 7951195 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthosorb pins
Number of subjects: 43
Study 7951195 — intervention group
Group type: COMPARATOR
Intervention: Cortical screw (2.7-mm)
Number of subjects: 43
Study 3303823 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 0
Study 3303823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum alone
Number of subjects: 0
Study 3303823 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum + Methotrexate
Number of subjects: 0